Family Office

Updated:

Jaguar Animal Health

Jaguar Animal Health is a San Francisco- and New York-based family office investing in animal health pharmaceuticals and biotechnology.

Jaguar Animal Health

Jaguar Animal Health's corporate identity and founding details are not publicly documented. The firm operates from offices in San Francisco, California, and New York, New York, but no founding year, named principals, or wealth origin appear in available records. Its name aligns with a historical public pharmaceutical company (Jaguar Health, Inc.) that pivoted to animal health, but the family-office entity's connection to that legacy is unconfirmed. Investment focus centers on animal health pharmaceuticals, particularly gastrointestinal and infectious disease therapeutics for companion and production animals. Typical holdings include veterinary drug development companies and diagnostic platforms, though specific portfolio companies or deals are not disclosed. Geographic activities appear limited to the United States, with no known international deployment. No professionals headcount, AUM, or deployment figures have been released. The firm has no confirmed philanthropic or operating-company affiliates. No recent operational events (last 24 months) are verifiable from public sources. The firm's structural differentiation is unclear—it may function as a dedicated family office, a single-purpose investment vehicle for animal health deals, or a holding company. Its obscurity relative to the broader market distinguishes it only by its narrow sector focus.

General information

Firm type

Family Office

Year founded

AUM

Undisclosed

Location

Region

North America

Country

United States

City

San Francisco

Corporate office

San Francisco, California, United States

Additional offices

New York, New York, United States

Sector focus

Animal HealthVeterinaryPharmaceuticalsBiotechnology

Frequently asked questions

Who runs investment decisions at Jaguar Animal Health?

Jaguar Animal Health does not publicly disclose its principals or investment committee members. No individual names appear in available records, leaving decision-making structures opaque.

What investment stage does Jaguar Animal Health target?

The firm's stage focus is unclear. Its name and sector alignment with veterinary pharmaceuticals suggest a preference for early-stage development or later-stage approved products, but no deals are on record.

Does Jaguar Animal Health participate in fund commitments or direct deals?

No public data indicates fund commitments or direct investment vehicles. The firm may operate as a direct deal investor or hold concentrated positions, but evidence is absent.

What sectors does Jaguar Animal Health explicitly avoid?

No explicit avoidance statements exist. Its apparent focus on animal health implies it does not typically invest in human pharmaceuticals or non-biotech sectors.

How does Jaguar Animal Health source proprietary deal flow?

Deal sourcing mechanisms are undisclosed. Without named partners or advisory links, the firm's pipeline may rely on relationships within the veterinary industry or on opportunistic placements.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on family offices?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo